SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

CytoMed Therapeutics Ltd
Date: June 18, 2025 · CIK: 0001873093 · Accession: 0000000000-25-006436

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288033

Date
June 18, 2025
Author
Division of
Form
UPLOAD
Company
CytoMed Therapeutics Ltd

Letter

Re: CytoMed Therapeutics Limited Registration Statement on Form F-3 Filed June 13, 2025 File No. 333-288033 Dear Choo Chee Kong:

June 18, 2025

Choo Chee Kong Chairman & Director CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Yarona L. Yieh, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 18, 2025

Choo Chee Kong
Chairman & Director
CytoMed Therapeutics Limited
1 Commonwealth Lane
#08-22
Singapore 149544

 Re: CytoMed Therapeutics Limited
 Registration Statement on Form F-3
 Filed June 13, 2025
 File No. 333-288033
Dear Choo Chee Kong:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tim Buchmiller at 202-551-3635 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Yarona L. Yieh, Esq.
</TEXT>
</DOCUMENT>